Rothschild & Co has initiated coverage on Stryker Corp (SYK) with a Neutral rating, marking the firm's first assessment of the medical technology company. Based in Portage, Michigan, Stryker is known for its products and services that enhance patient and healthcare outcomes, employing 53,000 full-time staff.
As of September 17, 2025, Stryker's stock is priced at $370.23. The company, which operates in the Health Care sector, offers a range of products in MedSurg, Neurotechnology, and Orthopaedics. Its MedSurg segment includes surgical equipment and patient safety technologies, while Neurotechnology features neurosurgical and neurovascular products. Orthopaedics primarily focuses on implants for joint replacements and trauma surgeries.
Rothschild's Neutral rating reflects a balanced view of Stryker's investment potential based on comprehensive research and analysis of the company's market position and growth prospects. The firm’s decision underscores the importance of considering various factors, including company fundamentals and competitive dynamics, when evaluating investment opportunities.
Stryker's current market capitalization stands at $140.2 billion, with a P/E ratio of 47.63 and an EPS of 7.62. The company has a dividend yield of 92.2%. Upcoming earnings are scheduled for July 29, 2026, with an EPS estimate of $3.51 and a revenue estimate of $6.6 billion. Analyst consensus indicates a Buy rating, with recent actions reflecting a mix of maintained ratings across various firms.
This update provides insight into the evolving landscape of analyst opinions on Stryker Corp, which can change as new information becomes available.